Publications by authors named "J P Schellens"
Background: The Alpe-DPD study (NCT02324452) demonstrated that prospective genotyping and dose-individualization using four alleles in DPYD (DPYD*2A/rs3918290, c.1236G > A/rs75017182, c.2846A > T/rs67376798 and c.
View Article and Find Full Text PDFPurpose: The development of resistance limits the clinical benefit of BRAF and MEK inhibitors (BRAFi/MEKi) in BRAFV600-mutated melanoma. It has been shown that short-term treatment (14 days) with vorinostat was able to initiate apoptosis of resistant tumor cells. We aimed to assess the antitumor activity of sequential treatment with vorinostat following BRAFi/MEKi in patients with BRAFV600-mutated melanoma who progressed after initial response to BRAFi/MEKi.
View Article and Find Full Text PDFThe CoLab score was developed and externally validated to rule out COVID-19 among suspected patients presenting at the emergency department. We hypothesized a within-patient decrease in the CoLab score over time in an intensive care unit (ICU) cohort. Such a decrease would create the opportunity to potentially rule out the need for isolation when the infection is overcome.
View Article and Find Full Text PDFArticle Synopsis
- - Dihydropyrimidine dehydrogenase (DPD) deficiency is a major cause of severe toxic reactions in patients treated with fluoropyrimidine (FP) drugs; a meta-analysis was done to evaluate the effect of specific DPYD gene variants and other clinical factors on predicting severe toxicity.
- - The study focused on Caucasian patients not receiving FP dose adjustments due to DPD deficiency, finding that the prevalence of severe toxicity (G4-5) after 12 weeks was 7.3%, with certain genetic variants notably increasing risk.
- - Significant findings indicate that combining DPYD variant data with clinical characteristics greatly enhances the ability to identify patients at risk for extreme FP-related toxicity, emphasizing the importance of
Purpose: To describe the effect of dexamethasone and tocilizumab on regional lung mechanics over admission in all mechanically ventilated COVID-19 patients.
Materials And Methods: Dynamic compliance, alveolar overdistension and collapse were serially determined using electric impedance tomography (EIT). Patients were categorized into three groups; no anti-inflammatory therapy, dexamethasone therapy, dexamethasone + tocilizumab therapy.